Advanced search
Publication Cover
Leukemia & Lymphoma Volume 52, 2011 - Issue 7
Submit an article Journal homepage
384
Views
16
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Superior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by a free light chain- and M-protein-based model: extended follow-up of a phase II trial

Dominik Dytfeld
,
Kent A. GriffithBiostatistics Unit, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
,
Judah FriedmanUniversity Hospitals Geauga Medical Center, Chardon, OH, USA
,
Daniel LebovicDivision of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA
,
Colleen HarveyDivision of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA
,
Mark S. KaminskiDivision of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA
&
Andrzej J. JakubowiakDivision of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USACorrespondence[email protected]
 show all
Pages 1271-1280 | Received 26 Nov 2010, Accepted 25 Feb 2011, Published online: 23 Jun 2011

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Ravi Vij, Michael Wang, Sundar Jagannath, Ruben Niesvizky, Andrzej J. Jakubowiak, Edward Kavalerchik, Mei Huang & David S. Siegel. (2015) Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma. Leukemia & Lymphoma 56:10, pages 2959-2961.
Read now
David H. Vesole. (2011) Predicting outcomes in multiple myeloma: do we really need another model?. Leukemia & Lymphoma 52:7, pages 1170-1172.
Read now

Articles from other publishers (14)

Aiko Sawazaki, Chiharu Sugimori, Masaki Yamaguchi & Shinji Nakao. (2023) Intermediate-dose cyclophosphamide and bortezomib for PBSC mobilization in multiple myeloma. Transfusion and Apheresis Science 62:3, pages 103649.
Crossref
Xiaoyu Yan, Xu Steven Xu, Katja C. Weisel, Maria‐Victoria Mateos, Pieter Sonneveld, Meletios A. Dimopoulos, Saad Zafar Usmani, Nizar J. Bahlis, Thomas Puchalski, Jon Ukropec, Kevin Bellew, Qi Ming, Steven Sun & Honghui Zhou. (2020) Early M‐Protein Dynamics Predicts Progression‐Free Survival in Patients With Relapsed/Refractory Multiple Myeloma. Clinical and Translational Science 13:6, pages 1345-1354.
Crossref
Clément Bailly, Thomas Carlier, Bastien Jamet, Thomas Eugene, Cyrille Touzeau, Michel Attal, Cyrille Hulin, Thierry Facon, Xavier Leleu, Aurore Perrot, Laurent Garderet, Margaret Macro, Denis Caillot, Philippe Moreau, Françoise Kraeber-Bodéré & Caroline Bodet-Milin. (2018) Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM Study. Clinical Cancer Research 24:21, pages 5219-5224.
Crossref
Tadeusz Kubicki, Dominik Dytfeld, Aleksandra Baszczuk, Ewa Wysocka, Mieczysław Komarnicki & Krzysztof Lewandowski. (2017) Clinical usefulness of serum free light chains measurement in patients with multiple myeloma: comparative analysis of two different tests. Postępy Higieny i Medycyny Doświadczalnej 71:0, pages 40-46.
Crossref
Carolina Terragna, Daniel Remondini, Marina Martello, Elena Zamagni, Lucia Pantani, Francesca Patriarca, Annalisa Pezzi, Giuseppe Levi, Massimo Offidani, Ilaria Proserpio, Giovanni De Sabbata, Paola Tacchetti, Clotilde Cangialosi, Fabrizio Ciambelli, Clara Virginia Viganò, Flores Angela Dico, Barbara Santacroce, Enrica Borsi, Annamaria Brioli, Giulia Marzocchi, Gastone Castellani, Giovanni Martinelli, Antonio Palumbo & Michele Cavo. (2015) The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD). Oncotarget 7:9, pages 9666-9679.
Crossref
Giuseppe Aprile, Caterina Fontanella, Marta Bonotto, Karim Rihawi, Stefania Eufemia Lutrino, Laura Ferrari, Mariaelena Casagrande, Elena Ongaro, Massimiliano Berretta, Antonio Avallone, Gerardo Rosati, Francesco Giuliani & Gianpiero Fasola. (2015) Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials. Oncotarget 6:30, pages 28716-28730.
Crossref
Dominik Dytfeld, Shaun Rosebeck, Malathi Kandarpa, Anoop Mayampurath, Dattatreya Mellacheruvu, Mattina M. Alonge, Lambert Ngoka, Jagoda Jasielec, Paul G. Richardson, Samuel Volchenboum, Alexey I. Nesvizhskii, Arun Sreekumar & Andrzej J. Jakubowiak. (2015) Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens. British Journal of Haematology 170:1, pages 66-79.
Crossref
S Lonial & K C Anderson. (2013) Association of response endpoints with survival outcomes in multiple myeloma. Leukemia 28:2, pages 258-268.
Crossref
Cara Rosenbaum, Jagoda Jasielec, Jacob Laubach, Claudia Paba Prada, Paul Richardson & Andrzej J. Jakubowiak. (2013) Evolving Strategies in the Initial Treatment of Multiple Myeloma. Seminars in Oncology 40:5, pages 592-601.
Crossref
Dominik Dytfeld. (2013) Translational research w szpiczaku plazmocytowym polsk? szans? na przyspieszenie?. Acta Haematologica Polonica 44:3, pages 196-199.
Crossref
Ruben Niesvizky, Tomer M. Mark, Maureen Ward, David S. Jayabalan, Roger N. Pearse, Megan Manco, Jessica Stern, Paul J. Christos, Lena Mathews, Tsiporah B. Shore, Faiza Zafar, Karen Pekle, Zhaoying Xiang, Scott Ely, Donna Skerret, Selina Chen-Kiang, Morton Coleman & Maureen E. Lane. (2013) Overcoming the Response Plateau in Multiple Myeloma: A Novel Bortezomib-Based Strategy for Secondary Induction and High-Yield CD34+ Stem Cell Mobilization. Clinical Cancer Research 19:6, pages 1534-1546.
Crossref
Jagoda K Jasielec & Andrzej J Jakubowiak. (2013) Current approaches to the initial treatment of symptomatic multiple myeloma. International Journal of Hematologic Oncology 2:1, pages 61-70.
Crossref
Andrzej J. JakubowiakDominik DytfeldKent A. GriffithDaniel LebovicDavid H. VesoleSundar Jagannath, Ammar Al-ZoubiTara AndersonBrian NordgrenKristen Detweiler-ShortKeith Stockerl-Goldstein, Asra AhmedTerri JobkarDiane E. DureckiKathryn McDonnellMelissa MietzelDaniel CourielMark KaminskiRavi Vij. (2012) A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 120:9, pages 1801-1809.
Crossref
Andrzej J. JakubowiakKent A. GriffithDonna E. ReeceCraig C. HofmeisterSagar LonialTodd M. ZimmermanErica L. CampagnaroRobert L. SchlossmanJacob P. LaubachNoopur S. RajeTara AndersonMelissa A. MietzelColleen K. HarveySandra M. WearJennifer C. BarrickmanCraig L. Tendler, Dixie-Lee Esseltine, Susan L. KelleyMark S. KaminskiKenneth C. AndersonPaul G. Richardson. (2011) Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. Blood 118:3, pages 535-543.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.